PROTAC Library - PROTAC® / BOC Sciences

Structure	Catalog	Product Name	CAS	E3 Ligase	Target	Inquiry
	BPL-201253	(2S)-2-Acrylamido-N5-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)-N1-(3-((5-(2-methyl-5-(3-(trifluoromethyl)benzamido)benzamido)pyrimidin-2-yl)amino)phenyl)pentanediamide	2743380-10-9	CRBN	BTK	Inquiry
Molecular Weight: 1072.11 Molecular Formula: C55H56F3N11O9 Density: 1.397±0.06 g/cm3 Description: It is a covalent inhibitor-based chimeric degrader used to degrade BTK and BLK kinases.
	BPL-201254	2-(2-(2-(((S)-1-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethoxy)ethyl (2S,4S)-1-acryloyl-4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidine-2-carboxylate	2743380-11-0	VHL	BTK BLK	Inquiry
Molecular Weight: 1029.19 Molecular Formula: C53H60N10O10S Boiling Point: 1225.0±65.0°C at 760 Torr Density: 1.39±0.1 g/cm3 Description: It is a covalent inhibitor-based chimeric degrader used to degrade BTK and BLK kinases.
	BPL-201255	(S)-2-Acrylamido-N5-(8-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-8-oxooctyl)-N1-(3-((5-(2-methyl-5-(3-(trifluoromethyl)benzamido)benzamido)pyrimidin-2-yl)amino)phenyl)pentanediamide		VHL	BTK	Inquiry
Molecular Weight: 1243.42 Molecular Formula: C64H73F3N12O9S Description: It is a covalent inhibitor-based chimeric degrader used to degrade BTK and BLK kinases.
	BPL-201256	2-(2-(2-(((S)-1-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethoxy)ethyl (2S,4S)-4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-propionylpyrrolidine-2-carboxylate	2743380-13-2	VHL	BTK	Inquiry
Molecular Weight: 1031.21 Molecular Formula: C53H62N10O10S Boiling Point: 1213.0±65.0°C at 760 Torr Density: 1.40±0.1 g/cm3 Description: It is a covalent inhibitor-based chimeric degrader used to degrade BTK and BLK kinases.
	BPL-201257	(2S)-N5-(8-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)-N1-(3-((5-(2-methyl-5-(3-(trifluoromethyl)benzamido)benzamido)pyrimidin-2-yl)amino)phenyl)-2-propionamidopentanediamide	2743380-14-3	CRBN	BTK	Inquiry
Molecular Weight: 1074.13 Molecular Formula: C55H58F3N11O9 Density: 1.391±0.06 g/cm3 Description: It is a covalent inhibitor-based chimeric degrader used to degrade BTK and BLK kinases.
	BPL-201258	2-(2,6-Dioxo-3-piperidinyl)-4-[[2-[2-[[6-[[(3β,5α,17β)-17-(7-isoquinolinyl)androstan-3-yl]methylamino]hexyl]oxy]ethoxy]ethyl]amino]-1H-isoindole-1,3(2H)-dione	2374807-07-3	CRBN	CDK8	Inquiry
Molecular Weight: 860.15 Molecular Formula: C52H69N5O6 Density: 1.24±0.1 g/cm3 Description: It is a highly potent and selective CDK8 steroidal inhibitor and degrader.
	BPL-201259	3-[2-[2-[[2-(2,6-Dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]ethoxy]ethoxy]-N-[(3β,5α,17β)-17-(7-isoquinolinyl)androstan-3-yl]-N-methylpropanamide	2209085-24-3	CRBN	CDK8	Inquiry
Molecular Weight: 832.06 Molecular Formula: C49H61N5O7 Density: 1.30±0.1 g/cm3 Description: It is a highly potent and selective CDK8 steroidal inhibitor and degrader.
	BPL-201260	NC-1	2702938-91-6	CRBN	BTK	Inquiry
Molecular Weight: 947.06 Molecular Formula: C50H58N8O11 Boiling Point: 1083.9±65.0°C at 760 Torr Density: 1.39±0.1 g/cm3 Description: It shows enhanced inhibition of B cell activation compared to ibrutinib and exhibits potent degradation of BTK in patient-derived primary chronic lymphocytic leukemia cells.
	BPL-201261	IR-1	2702938-81-4	CRBN	BTK	Inquiry
Molecular Weight: 947.02 Molecular Formula: C49H54N8O12 Boiling Point: 1099.2±65.0°C at 760 Torr Density: 1.41±0.1 g/cm3 Description: It shows enhanced inhibition of B cell activation compared to ibrutinib and exhibits potent degradation of BTK in patient-derived primary chronic lymphocytic leukemia cells.
	BPL-201262	IR-2	2702938-88-1	CRBN	BTK	Inquiry
Molecular Weight: 945.04 Molecular Formula: C50H56N8O11 Boiling Point: 1096.5±65.0°C at 760 Torr Density: 1.39±0.1 g/cm3 Description: It shows enhanced inhibition of B cell activation compared to ibrutinib and exhibits potent degradation of BTK in patient-derived primary chronic lymphocytic leukemia cells.
	BPL-201263	(αZ,3S)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-α-[17-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]-3,6,9,12,15-pentaoxaheptadec-1-ylidene]-β-oxo-1-piperidinepropanenitrile	2702938-96-1	CRBN	BTK	Inquiry
Molecular Weight: 972.03 Molecular Formula: C50H53N9O12 Boiling Point: 1145.1±65.0°C at 760 Torr Density: 1.42±0.1 g/cm3 Description: It shows enhanced inhibition of B cell activation compared to ibrutinib and exhibits potent degradation of BTK in patient-derived primary chronic lymphocytic leukemia cells.
	BPL-201264	(αZ,3S)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-α-[17-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]-6,9,12,15-tetraoxaheptadec-1-ylidene]-β-oxo-1-piperidinepropanenitrile	2702938-86-9	CRBN	BTK	Inquiry
Molecular Weight: 970.05 Molecular Formula: C51H55N9O11 Boiling Point: 1141.9±65.0°C at 760 Torr Density: 1.40±0.1 g/cm3 Description: It shows enhanced inhibition of B cell activation compared to ibrutinib and exhibits potent degradation of BTK in patient-derived primary chronic lymphocytic leukemia cells.
	BPL-201265	(Z)-18-((S)-3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)-16,16-dimethyl-3,6,9,12-tetraoxanonadec-17-ene-19-nitrile		CRBN	BTK	Inquiry
Molecular Weight: 998.11 Molecular Formula: C53H59N9O11 Boiling Point: 1141.1±65.0°C at 760 Torr Density: 1.37±0.1 g/cm3 Description: It is a reversible covalent BTK PROTAC. It shows enhanced inhibition of B cell activation compared to ibrutinib and exhibits potent degradation of BTK in patient-derived primary chronic lymphocytic leukemia cells.
	BPL-201266	RC-0a		CRBN	BTK	Inquiry
Molecular Weight: 927.97 Molecular Formula: C48H49N9O11 Description: It is a reversible covalent BTK PROTAC. It shows enhanced inhibition of B cell activation compared to ibrutinib and exhibits potent degradation of BTK in patient-derived primary chronic lymphocytic leukemia cells.
	BPL-201267	RC-0b		CRBN	BTK	Inquiry
Molecular Weight: 883.92 Molecular Formula: C46H45N9O10 Description: It is a reversible covalent BTK PROTAC. It shows enhanced inhibition of B cell activation compared to ibrutinib and exhibits potent degradation of BTK in patient-derived primary chronic lymphocytic leukemia cells.
	BPL-201268	RC-0c		VHL	BTK	Inquiry
Molecular Weight: 1281.51 Molecular Formula: C65H80N14O12S Description: It is a reversible covalent BTK PROTAC. It shows enhanced inhibition of B cell activation compared to ibrutinib and exhibits potent degradation of BTK in patient-derived primary chronic lymphocytic leukemia cells.
	BPL-201269	RC-0d		VHL	BTK	Inquiry
Molecular Weight: 1193.40 Molecular Formula: C61H72N14O10S Description: It is a reversible covalent BTK PROTAC. It shows enhanced inhibition of B cell activation compared to ibrutinib and exhibits potent degradation of BTK in patient-derived primary chronic lymphocytic leukemia cells.
	BPL-201270	RC-0e		VHL	BTK	Inquiry
Molecular Weight: 1149.35 Molecular Formula: C59H68N14O9S Description: It is a reversible covalent BTK PROTAC. It shows enhanced inhibition of B cell activation compared to ibrutinib and exhibits potent degradation of BTK in patient-derived primary chronic lymphocytic leukemia cells.
	BPL-201271	RC-0f		VHL	BTK	Inquiry
Molecular Weight: 1105.30 Molecular Formula: C57H64N14O8S Description: It is a reversible covalent BTK PROTAC. It shows enhanced inhibition of B cell activation compared to ibrutinib and exhibits potent degradation of BTK in patient-derived primary chronic lymphocytic leukemia cells.
	BPL-201272	RC-0g		CRBN	BTK	Inquiry
Molecular Weight: 1080.13 Molecular Formula: C54H57N13O12 Description: It is a reversible covalent BTK PROTAC. It shows enhanced inhibition of B cell activation compared to ibrutinib and exhibits potent degradation of BTK in patient-derived primary chronic lymphocytic leukemia cells.